赵松峰,张亚玲,张 晓,师秀琴,张 祥,张晓坚
(1.郑州大学第一附属医院药学部,河南 郑州 450052;2.郑州大学第一附属医院《肿瘤基础与临床》编辑部,河南 郑州 450052)
盐酸羟考酮缓释片治疗胃癌患者中重度癌痛的临床疗效观察
赵松峰1,张亚玲2,张晓1,师秀琴1,张祥1,张晓坚1
(1.郑州大学第一附属医院药学部,河南 郑州 450052;2.郑州大学第一附属医院《肿瘤基础与临床》编辑部,河南 郑州 450052)
目的探讨盐酸羟考酮缓释片用于胃癌患者中重度癌痛的临床疗效和毒副反应。方法135例胃癌中重度癌痛患者均接受口服盐酸羟考酮缓释片控制癌痛,初始剂量10~20 mg/次,q12 h,用药过程中根据疼痛评估情况进行剂量调整,直至癌痛控制良好。2周后采取NRS评分法进行疼痛评分,并观察疼痛缓解情况、生活质量、药物毒副反应等。结果所有135例患者治疗后NRS评分为(1.68±0.98)分,明显低于治疗前的(7.22±2.13)分,差异有统计学意义(P>0.05)。治疗后总疼痛缓解率为92.6%。生活质量改善率为74.1%。主要毒副反应为恶心呕吐、便秘、嗜睡等,均为轻度,未影响治疗的顺利进行。结论盐酸羟考酮缓释片用于胃癌患者能够良好控制中重度癌痛,明显改善患者的生活质量,且用药较为安全。
盐酸羟考酮缓释片;胃癌;中重度癌痛
[Abstract]ObjectiveTo observe efficacy and toxicities of oxycodone hydrochloride controlled release tablet in the treatment of gastric cancer patients with moderate to severe cancer pain.MethodsThe 135 cases of gastric cancer patients with moderate to severe cancer pain were was administrated with oxycodone hydrochloride controlled release tablet. The starting dose was 10 to 20 mg every 12 h, the dose was adjusted according to pain degree. Every patients were treated for two weeks. The pain relief, quality of life and toxicities were evaluated after treatment.ResultsFor the 135 patients, the NRS score after treatment (1.68±0.98) was lower than that before treatment (7.22±2.13) (P<0.05). The cancer pain relief rate was 92.6%. The improvement rate of quality of life was 74.1%. The main toxicities were light degree nausea and vomiting, constipation drowsiness.ConclusionOxycodone hydrochloride controlled release tablet can control cancer pain and improve quality of life in the treatment of gastric cancer patients with moderate to severe cancer pain, and has good safety.
[Key words]oxycodone hydrochloride controlled release tablet; gastric cancer; moderate to severe cancer pain
随着肿瘤治疗技术的提高以及人民健康意识等增强,恶性肿瘤患者对在延长生存时间的同时对生活质量的要求也越来越高。而且近年来,恶性肿瘤的发病率均呈上升趋势。这使得恶性肿瘤患者,特别是晚期患者,其所发生的癌痛,越来越受到关注。目……